Detalles de la búsqueda
1.
Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial.
Hepatology
; 67(6): 2113-2126, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29473975
2.
Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.
Gastroenterology
; 152(6): 1372-1382.e2, 2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28193518
3.
Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection.
Gastroenterology
; 152(1): 164-175.e4, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27720838
4.
Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial.
Hepatology
; 65(2): 439-450, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27770561
5.
Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study.
Hepatology
; 66(3): 736-745, 2017 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28256747
6.
Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure.
Hepatology
; 66(6): 1794-1804, 2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-28688129
7.
Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis.
Liver Int
; 38(9): 1583-1591, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29461687
8.
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.
Ann Intern Med
; 165(9): 625-634, 2016 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27537841
9.
Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE.
Clin Infect Dis
; 62(1): 32-6, 2016 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26371152
10.
Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial.
J Hepatol
; 65(6): 1112-1119, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27542322
11.
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.
Lancet
; 386(10003): 1537-45, 2015 Oct 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-26456905
12.
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.
Lancet
; 385(9973): 1087-97, 2015 Mar 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-25467560
13.
Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial.
Lancet
; 385(9973): 1075-86, 2015 Mar 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-25467591
14.
Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial.
Ann Intern Med
; 163(1): 1-13, 2015 Jul 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-25909356
15.
Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent.
J Hepatol
; 63(3): 564-72, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25895428
16.
The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis.
Gastroenterology
; 147(2): 366-76.e6, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24727022
17.
Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trials.
J Hepatol
; 61(2): 200-9, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24747798
18.
Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response.
J Hepatol
; 60(4): 748-56, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24362076
19.
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial.
Gastroenterology
; 145(5): 1035-1044.e5, 2013 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-23924660
20.
Determination of posaconazole levels in toenails of adults with onychomycosis following oral treatment with four regimens of posaconazole for 12 or 24 weeks.
Antimicrob Agents Chemother
; 55(9): 4424-6, 2011 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-21746944